SCHEMBL3100804

SCHEMBL3100804

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2c(N)cccc2F)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 5/20 0.42
LARS1 Q9P2J5 1/20 0.41
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
KAT6A Q92794 3/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PLG P00747 1/20 0.37
KAT7 O95251 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
KAT6B Q8WYB5 1/20 0.36
KAT5 Q92993 1/20 0.36
KAT8 Q9H7Z6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096609 1.00 F2 (0.42) F2LARS1NPC1RAB9AMEN1
SCHEMBL3079467 0.94 F2 (0.43) F2LARS1NPC1RAB9AMEN1
SCHEMBL3096740 0.93 LARS1 (0.41) F2LARS1NPC1RAB9AMEN1
SCHEMBL3084783 0.92 LARS1 (0.40) F2LARS1NPC1RAB9AMEN1
SCHEMBL3089105 0.92 LARS1 (0.40) F2LARS1MEN1KMT2ALMNA
SCHEMBL3086182 0.89 LARS1 (0.42) F2LARS1NPC1RAB9ALMNA
SCHEMBL3093304 0.89 LARS1 (0.42) F2LARS1NPC1RAB9ALMNA
SCHEMBL3100518 0.89 NPC1 (0.51) F2LARS1NPC1RAB9AMEN1
SCHEMBL3096503 0.89 LARS1 (0.45) F2LARS1NPC1MEN1KMT2A
SCHEMBL3101165 0.89 NPC1 (0.51) F2LARS1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 F2 4128/4885LARS1 1976/4885NPC1 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.